Cargando…

The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment

Although cellular and molecular bases of proliferative diabetic retinopathy are only partially understood, it is evident that this complication of diabetes is characterized by the formation of new vessels inside the retina showing abnormal architecture and permeability. This process, if not controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tremolada, Gemma, Del Turco, Claudia, Lattanzio, Rosangela, Maestroni, Silvia, Maestroni, Anna, Bandello, Francesco, Zerbini, Gianpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332167/ https://www.ncbi.nlm.nih.gov/pubmed/22566995 http://dx.doi.org/10.1155/2012/728325

Ejemplares similares

Endothelial Progenitor Cells Carrying Monocyte Markers Are Selectively Abnormal in Type 1 Diabetic Patients With Early Retinopathy
por: Zerbini, Gianpaolo, et al.
Publicado: (2012)

Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy
por: Takayama, Kei, et al.
Publicado: (2021)

Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy
por: Zerbini, Gianpaolo, et al.
Publicado: (2023)

Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy
por: Parravano, Mariacristina, et al.
Publicado: (2022)

Diabetes has no additional impact on retinal ganglion cell loss in a mouse model of spontaneous glaucoma
por: Maestroni, Silvia, et al.
Publicado: (2022)

Topical nerve growth factor prevents neurodegenerative and vascular stages of diabetic retinopathy
por: Zerbini, Gianpaolo, et al.
Publicado: (2022)

Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy
por: Nguyen, Quan Dong, et al.
Publicado: (2023)

Short-and Long-Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy
por: Bucolo, Claudio, et al.
Publicado: (2021)

Erratum to “Detergent-Enzymatic Decellularization of Swine Blood Vessels: Insight on Mechanical Properties for Vascular Tissue Engineering”
por: Pellegata, Alessandro F., et al.
Publicado: (2014)

Detergent-Enzymatic Decellularization of Swine Blood Vessels: Insight on Mechanical Properties for Vascular Tissue Engineering
por: Pellegata, Alessandro F., et al.
Publicado: (2013)

Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons’ in Hamlet's dilemma?
por: Azad, Rajvardhan
Publicado: (2011)

The Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy
por: Bunge, Casey C., et al.
Publicado: (2023)

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008)

Optical Coherence Tomography Biomarkers of Inflammation in Diabetic Macular Edema Treated by Fluocinolone Acetonide Intravitreal Drug-Delivery System Implant
por: Arrigo, Alessandro, et al.
Publicado: (2020)

Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections
por: Levin, Ariana M, et al.
Publicado: (2017)

Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy
por: Zhang, Yunda, et al.
Publicado: (2021)

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
por: Bahr, Tyler A., et al.
Publicado: (2023)

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
por: Ribeiro de Carvalho, Giuliana, et al.
Publicado: (2020)

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
por: Arrigo, Alessandro, et al.
Publicado: (2022)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
por: Zhao, Yue, et al.
Publicado: (2018)

Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines
por: Maestroni, Georges
Publicado: (2020)

Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
por: Fernando Arevalo, J.
Publicado: (2013)

Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era
por: Hsu, Ya-Jui, et al.
Publicado: (2014)

Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: A systematic review and meta-analysis
por: Fu, Peng, et al.
Publicado: (2023)

Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy
por: Tsubota, Kinya, et al.
Publicado: (2019)

The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
por: Kuiper, Esther J., et al.
Publicado: (2008)

Bilateral Hypertensive Retinopathy Complicated with Retinal Neovascularization: Panretinal Photocoagulation or Intravitreal Anti-VEGF Treatment?
por: Georgiadis, Odysseas, et al.
Publicado: (2014)

A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy
por: Raman, Rajiv, et al.
Publicado: (2022)

Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation
por: Hu, Wei-Hui, et al.
Publicado: (2022)

Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy
por: El-Batarny, Ashraf M
Publicado: (2007)

The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy
por: Al-Kharashi, Abdullah, et al.
Publicado: (2016)

Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy
por: Xu, Jun, et al.
Publicado: (2020)

Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: a systematic review
por: Dervenis, Panagiotis, et al.
Publicado: (2021)

Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy
por: Wang, Weiwei, et al.
Publicado: (2023)

Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
por: Linghu, Dandan, et al.
Publicado: (2022)

Fisetin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF
por: Lai, Meihua, et al.
Publicado: (2023)

Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF
por: Ridano, Magali E., et al.
Publicado: (2017)

VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients
por: Rezzola, Sara, et al.
Publicado: (2021)

The remote effects of intravitreal anti-VEGF therapy
por: Balta, F, et al.
Publicado: (2016)

Issues with Intravitreal Administration of Anti-VEGF Drugs
por: Schargus, Marc, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nqj127fbqltm45ql9cvo29cqvm